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Tumour lysis syndrome (TLS) is a rare side eﬀect of chemotherapy for solid tumours. It describes the metabolic derangements
following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic
derangement and renal failure. Treatment involves rehydration and correction of metabolic abnormalities. TLS should be consid-
ered in high risk groups. We report a case of TLS in a patient with metastatic gastrointestinal stromal tumour treated with imatinib
mesylate. To our knowledge, this is the ﬁrst reported case.
Copyright © 2007 Elizabeth M. Pinder et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Gastrointestinal stromal tumour (GIST) is derived from
mesodermal tissue but its pathogenesis remains unclear [1].
It predominantly occurs in the wall of the gastrointestinal
tract and most are found in the stomach and small intestine
but have also been reported in the colon, rectum, oesopha-
gus, and extra-intestinal sites such as omentum, mesentery,
and retroperitoneum [2]. They occur in persons of either sex
usually over the age of 40 years [3]. The incidence is esti-
mated to be from 1000 to 6000 new cases a year in the United
States [2, 3]. The increasing use of immunohistochemistry,
in particular CD117, has increased awareness of existence of
GISTs amongst surgical pathologists [3].
Most GISTs have a gain of function mutation in the c-kit
proto-oncogeneresultinginligandindependentactivationof
theKITreceptortyrosinekinaseandunopposedstimulusfor
cell growth. Glivec selectively binds to and inhibits the activ-
ityofasmallnumberoftyrosinekinasesincludingABL,BCR
ABL, platelet derived growth factor receptor, and KIT [2, 4].
Results have shown that inhibition of active mutant c-kit ty-
rosine kinase by glivec is an eﬀective therapy for GISTs [4, 5].
Tumour lysis syndrome (TLS) is commonly seen fol-
lowing the treatment of exquisitely chemosensitive tumours,
such as haematological malignancies, and has been reported
in various solid tumours [6], but to our knowledge this is
the ﬁrst reported case of TLS occurring in a patient with
metastatic GIST following treatment with imatinib.
2. CASE REPORT
An 81-year-old man presented in 2002 with a two-day his-
tory of melaena and dizziness. He gave no history of pep-
tic ulcer disease, NSAID use, and denied signiﬁcant alco-
hol intake. His past medical history included systemic hyper-
tension, noninsulin dependent diabetes mellitus, ischaemic
heartdiseaseandgoutwhichwereallwellcontrolledonmed-
ication including allopurinol. He was also under regular re-
view for chronic lymphocytic leukaemia. This was stable and
he was not receiving active treatment.
Onexaminationhewashaemodynamicallystableandhis
abdomen was soft and nontender, with no palpable masses.
Per rectum, digital examination revealed only tarry black
stools consistent with melaena. Haemoglobin on admission2 Sarcoma
Figure 1: Findings at endoscopy. Note the large ulcerative gastric
mass on the greater curve of the stomach.
was 13g/dL, urea 28mmol/L, creatinine 142mmol/L, liver
function tests and clotting were normal. Endoscopy showed
a large focally ulcerative gastric mass on the greater curve
with prominent underlying vasculature (see Figure 1). The
lesion was injected with adrenaline and coagulated with ar-
gon plasma resulting in haemostasis. Over the following two
days, he had further episodes of melaena associated with a
haemoglobin of 6.7g/dL requiring multiple blood transfu-
sions.
Emergency laparotomy revealed a large ulcerated lesion
on the anterior wall of the distal half of the stomach not in-
volving the liver. A partial anterior gastrectomy with wide
excision of the gastric mass was performed. Histologically,
the tumour consisted of epithelioid cells with eosinophilic
cytoplasm, prominent nucleoli with a mitotic count of 9
per 30 high-power ﬁelds arranged in a whorled and pal-
isaded pattern with intervening myxoid stroma. Immuno-
histochemistry demonstrated tumour cell positivity for CD
117, smooth muscle actin, and CD 34. Staining for S100 pro-
tein, chromogranin and synaptophysin were negative, there-
fore supporting the morphological diagnosis of GIST (see
Figure 2). Surgical excision was complete and he made a
good recovery.
Initial postoperative follow up was performed but un-
fortunately he was lost to follow up. Thirty-two months
later, he was readmitted with sudden onset abdominal pain
and reduced appetite with no change in bowel habit or
weight loss. On examination, there was a large left upper
quadrant mass and mild tenderness in the left iliac fossa.
Haemoglobin was 11g/dL, he had mild renal impairment
(serum urea 11.3mmol/L, creatinine 139mmol/L) and there
wasanisolatedriseinalkalinephosphatase(456IU/L).Com-
puterised tomography (CT) scan demonstrated a large ab-
dominal mass involving the mesentery and abdominal wall
musculature measuring 20 × 11 × 25cm (see Figure 3).
Therewasnoevidenceoflivermetastases.Ultrasoundguided
biopsy of the abdominal mass conﬁrmed the diagnosis of re-
current metastatic GIST. Surgery wasconsideredinappropri-
ate and imatinib 400mg once daily was commenced. Two
Figure 2: Photomicrograph (x200) of the original resection speci-
men showing a cellular and epithelioid neoplasm.
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Figure 3: Computerised tomography scan of large abdominal mass
measuring 20 × 11 × 25cm.
dayslater,hebecameacutelyshortofbreathandoedematous
with poor urine output. Imatinib therapy was stopped and
his serum biochemistry showed classic features of TLS with
renal impairment, hyperuricaemia, elevated lactate dehydro-
genase (LDH), hyperkalaemia, and metabolic acidosis (see
Table 1). He was transferred to the High Dependency Unit
where he received CPAP, 2 units of blood, treatment to cor-
rect potassium levels, isoket, and a furosemide intravenous
infusion. Further intensive treatment including haemoﬁltra-
tion was considered inappropriate. His urine output initially
improved, however the peripherial oedema did not appear
to respond to intravenous furosemide infusion. Despite sup-
portive treatment, his condition deteriorated and he died 11
days after receiving his initial dose of imatinib.
Autopsy ﬁndings demonstrated a large mottled friable
grey tumour mass hanging on the under surface of the left
hemidiaphragm extending towards the left iliac fossa, mea-
suring 20 × 15 × 12cm but no bleeding into the peri-
toneum. It fragmented easily and showed signiﬁcant intra-
tumour haemorrhage. Within the tumour were occasionalElizabeth M. Pinder et al. 3
Table 1: Tabulation of renal function over a 47-day period starting from 35 days prior to treatment with imatinib to 11 days post
treatment. LDH = lactate dehydrogenase. Normal ranges: haemoglobin (13.0–18.0g/dL), white cell count (4.0–11.5E9/l), sodium (135–
145mmol/L), potassium (3.5–5.3mmol/L), urea (1–6.5mmol/L), creatinine (60–120µmol/L), phosphate (0.8–1.4mmol/L), corrected cal-
cium (2.2–2.6mmol/L), LDH (230–460iu/l), uric acid (100–400µmol/L).
Results Admission Day −35 Day −5D a y −3D a y + 2D a y + 3D a y + 4D a y + 6D a y + 1 0D a y + 1 1 ( d e a t h )
Haemoglobin 10.9 10.5 9.8 9.6 9.6 9.2 12.6 11.5 11.4
White cell count 10.1 15.10 14.3 14.1 14.3 11.30 8.7 10.9 3.5
Sodium 135 136 136 144 146 150 142 145 146
Potassium 5.1 5.2 5.2 6.3 6.4 4.4 5.4 3.9 4.1
Urea 11.3 19.6 34.8 28 31.4 31.5 17.1 16.5 21.9
Creatinine 139 228 270 148 163 176 115 98 128
Phosphate — — — — 1.53 — — 1.15 1.61
Calcium — — — — 2.43 — — 2.32 2.31
LDH — — — — 686 — — — —
Uric acid — — — — 574 — — — —
Figure4:Photomicrograph(x200)ofrepresentativeareaoftumour
at post mortem. Note the small pyknotic nuclei and areas of amor-
phous myxoid stroma representing areas where the tumour cells
have disappeared. Other areas were virtually acellular.
areas of grey ﬁrm ﬂeshy tissue. Two separate tumour nodules
werepresentintheomentumandserosaofthedistalsigmoid
colon, consisting largely of grey ﬁrm ﬂeshy tissue measur-
ing 8 and 5cm, respectively. The main mass had invaded and
perforated the colonic splenic ﬂexure.
The perforation was localised and walled oﬀ with only
localised inﬂammation and no evidence of generalised peri-
tonitis or generalised sepsis elsewhere (e.g., splenic soften-
ing).Althoughtheperforationmayhavecontributedtomor-
bidity, it is our opinion, due to its limited extent, that it was
not the primary cause of death. Histologically, the vast ma-
jority of the main mass was hypocellular consisting of scat-
tered tumour cells staining positive with CD117 with py-
knotic nuclei and condensed cytoplasm (resembling mast
cells) in an abundant myxoid stroma (see Figure 4). The
changes demonstrated dramatic tumour cell kill consistent
with the eﬀects of imatinib. Areas of ﬂeshy tumour (includ-
ing the two separate nodules) were microscopically identi-
ﬁed as viable tumour. The vessel density of the tumour was
assessed at resection and post mortem, the latter in both in
areas of tumour melt and near normality. The vessel den-
sity appeared similar, but in the autopsy slides the vessels,
although of the same delicate calibre, are signiﬁcantly more
dilated (see Figure 5). This is likely to represent direct eﬀect
of the drug and theoretically could indicate leakiness of the
vessels. Alternatively but less likely is that it represents nor-
mal post mortem autolysis. Nevertheless, the vascular den-
sity is the same and thus the tumour “necrosis” cannot be
attributed to pure ischaemia.
Post mortem histology showed viable deposits of CLL in
the myocardium, liver, spleen, and kidneys and no evidence
tosuggestdirecteﬀectofimatinib.Whitecellcountwas14.30
three days prior to starting imatinib and 14.3 three days after
imatinib was commenced. There were no other signiﬁcant
pathologies to cause death, although there was evidence of
ischaemic heart disease and a small pumonary embolus. The
cause of death was attributed to tumour lysis syndrome oc-
curring as a direct consequence of imatinib treated GIST.
3. DISCUSSION
Tumour lysis syndrome is deﬁned as a life threatening meta-
bolic emergency usually associated with the chemotherapeu-
tic treatment of certain malignancies, particularly haema-
tological. Rapid cell death occurs a few hours to days af-
ter administration of treatment resulting in the release of
intracellular potassium, phosphate, uric acid, and other
purine metabolites, which overwhelm the kidneys’ capacity
for clearance. Hyperkalaemia, hyperphosphataemia, hyper-
uricaemia, and hypocalcaemia result. Underlying renal im-
pairment potentiates the risk of TLS.
This patient certainly had many of the features of TLS,
although he did not require renal replacement therapy as fol-
lows.
(i) There was massive tumour cell kill seen at post mor-
tem examination, hyperkalaemia, hyperuricaemia,
and hyperphosphataemia.4 Sarcoma
(a) (b)
Figure 5: (a) Photomicrograph of representative area of tumour at resection and (b) at post mortem stained with CD31, an endothelial
marker
(ii) Uric acid was not measured pretreatment, but the pa-
tient was on long-term allopurinol for gout, and it is
therefore likely that the serum uric acid was normal
when starting imatinib. It rose by at least by 40% on
day 3.
(iii) Incipient renal failure was corrected with vigorous ﬂu-
ids.However,hyperkalaemiaremainedaproblem.The
potassium, which was at the upper end of the normal
range for over a month preceding treatment, rose con-
siderably.
The signiﬁcant side eﬀects of imatinib that could have
been implicated in his death did not occur—at post mortem
there was neither ascites that might have caused respiratory
embarrassment, nor intraperitoneal bleeding from the very
haemorrhagic tumours.
At post mortem examination, there was no signiﬁcant
intra-abdominal sepsis, only a localised peritonitic reaction
around the splenic ﬂexure. Other organs showed the ex-
pected changes for a man of eighty one years old, that is,
moderate coronary artery disease, atheroma of the thoracic
and abdominal aorta, and congested lungs.
Although comorbid disease may have contributed to his
death, by far the greatest element was the tumour lysis in-
duced by imatinib. Manoeuvres to prevent this such as start-
ing with a lower dose of imatinib are thought not to be ap-
propriate for fear of not bringing the disease under control
(J. Verweij, personal communication).
3.1. Literaturereview
Primary surgical excision with good margins is the main-
stay of treatment of GIST with an overall ﬁve-year survival
rate for localised disease of 54% [7] .T h er e s p o n s er a t ew i t h
cytotoxic chemotherapy is extremely poor [3–5]. The risk
of recurrence is high with the liver and peritoneal surfaces
most commonly aﬀected [3, 8]. Imatinib was ﬁrst utilised
for metastatic GIST in 2000 [5] and has been consistently
shown to be the most speciﬁc and eﬀective treatment to date
[2–5]. In general, adverse events are minimal and tend to
include mild fatigue, periorbital oedema, nausea, diarrhoea,
intermittent muscle cramping, rash, headache, and abdomi-
nal pain [2, 4]. In approximately 5% of cases, severe toxicity
grade3to4adverseeventsoccurincludinggastrointestinalor
intratumour haemorrhage due to massive tumour necrosis,
which rarely can be fatal [3]. This is the ﬁrst reported case of
TLS occurring in a patient with metastatic GIST treated with
imatinib.
Imatinib is also an eﬀective treatment for chronic my-
eloid leukaemia and a case report has been published of TLS
occurring in one patient [9].
The most reliable parameters for TLS are laboratory in-
dices and clinical signs and symptoms, which typically occur
12–72 hours after commencement of cytotoxic therapy [10].
Although nonhaematological malignancies are consid-
eredlowriskfordevelopingTLSduetolongerdoublingtime,
low growth fraction, and slow response to treatment com-
pared with lymphoproliferative malignancies, there are nu-
merous case reports in patients with diﬀerent tumours in-
cluding small cell lung cancer, medulloblastoma but none
in patients with GIST. Such solid tumours tend to be very
chemosensitive, although TLS can occur in less sensitive tu-
mours if bulky metastatic disease is present.
Risk factors for TLS include bulky disease, elevated pre-
treatment LDH, compromised renal function, potentially
nephrotoxic drugs, and raised uric acid levels. The patient
discussed here had several risk factors: dehydration sec-
ondary to diarrhoea, compromised renal function, bulky tu-
mour, and use of nephrotoxic drugs (metformin, spironolac-
tone).
Much of the literature on TLS stresses the importance of
prevention by having a high index of suspicion for patients
with large chemosenstitive tumours. This can be achieved
byprophylactictreatmentwithallopurinol,pretreatmenthy-
dration, and alkalinization of urine [11]. There are limita-
tions in the use of allopurinol including slow onset of ac-
tion, insuﬃcient eﬃcacy in many high-risk patients (57% in
hyperuricamic patients) [12] and the possibility of allergicElizabeth M. Pinder et al. 5
reactions and interactions with chemotherapeutic agents.
There is also evidence to suggest that allopurinol is no longer
the recommended drug for prophylaxis or treatment of TLS
due to its inability to lower already established uric acid lev-
els.ItalsocanleadtoXanthineaccumulationwhichcancrys-
tallize and precipitate in the renal tubules [13]. An alterna-
tive to allopurinol is rasburicase, a recombinant urate oxi-
dase which has been shown to be more eﬀective than allop-
urinol in preventing and treating hyperuricaemia [14]. This
drug is not without side eﬀects or cost and is used mainly in
haematological malignancies with little experience in solid
tumours. It will however reduce the incidence and severity of
TLS.
We thus advise caution when treating advanced GIST
with imatinib and suggest a full assessment of risk factors
for TLS which include high tumour burden (high white cell
count >50 × 109/L and/or high LDH levels), elevated uric
acid levels, intensive cytoreductive therapy, and poor hydra-
tion [10].
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